Experience of Rwanda on COVID-19 Case Management: From Uncertainties to the Era of Neutralizing Monoclonal Antibodies

The management of COVID-19 in Rwanda has been dynamic, and the use of COVID-19 therapeutics has gradually been updated based on scientific discoveries. The treatment for COVID-19 remained patient-centered and entirely state-sponsored during the first and second waves. From the time of identification...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of environmental research and public health Vol. 19; no. 3; p. 1023
Main Authors:	Nkeshimana, Menelas, Igiraneza, Deborah, Turatsinze, David, Niyonsenga, Otto, Abimana, Deborah, Iradukunda, Cyprien, Bizimana, Emmanuel, Muragizi, Jean, Mumporeze, Lise, Lussungu, Laurent, Mugisha, Hackim, Mgamb, Elizabeth, Bigirimana, Noella, Rwagasore, Edison, Gatare, Swaibu, Mugabo, Hassan, Nsekuye, Olivier, Semakula, Muhammed, Sendegeya, Augustin, Rurangwa, Ephraim, Kalimba, Edgar, Musafiri, Sanctus, Ntihabose, Corneille, Seruyange, Eric, Bavuma, Charlotte, Twagirumugabe, Theogene, Nyamwasa, Daniel, Nsanzimana, Sabin
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 18-01-2022 MDPI
Subjects:	Anti-inflammatory agents Antibiotics Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Neutralizing - therapeutic use Anticoagulants Antiviral agents Case management Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - therapy COVID-19 vaccines Disease transmission Ebola virus Epidemics Health facilities Hospitals Humans Hyperglycemia Infections Inflammation Medical records Monoclonal antibodies Neutralizing Pandemics Patients Public health Quarantine Rwanda - epidemiology SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Task forces Vaccines Rwanda COVID-19 guidelines interventions outcomes Rwanda monoclonal antibodies
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!